CA3154881A1 - Her2/4-1bb bispecific fusion proteins for the treatment of cancer - Google Patents

Her2/4-1bb bispecific fusion proteins for the treatment of cancer Download PDF

Info

Publication number
CA3154881A1
CA3154881A1 CA3154881A CA3154881A CA3154881A1 CA 3154881 A1 CA3154881 A1 CA 3154881A1 CA 3154881 A CA3154881 A CA 3154881A CA 3154881 A CA3154881 A CA 3154881A CA 3154881 A1 CA3154881 A1 CA 3154881A1
Authority
CA
Canada
Prior art keywords
fusion protein
once
dose
weeks
interval
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3154881A
Other languages
English (en)
French (fr)
Inventor
Shane Olwill
Louis Matis
Ingmar BRUNS
Manuela Duerr
Rushdia Zareen YUSUF
Markus Zettl
Andrea ALLERSDORFER
Aizea Morales KASTRESANA
Corinna SCHLOSSER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pieris Pharmaceuticals GmbH
Original Assignee
Pieris Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals GmbH filed Critical Pieris Pharmaceuticals GmbH
Publication of CA3154881A1 publication Critical patent/CA3154881A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3154881A 2019-11-04 2020-11-04 Her2/4-1bb bispecific fusion proteins for the treatment of cancer Pending CA3154881A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962930512P 2019-11-04 2019-11-04
US62/930,512 2019-11-04
US202063080361P 2020-09-18 2020-09-18
US63/080,361 2020-09-18
PCT/EP2020/080892 WO2021089588A1 (en) 2019-11-04 2020-11-04 Her2/4-1bb bispecific fusion proteins for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3154881A1 true CA3154881A1 (en) 2021-05-14

Family

ID=73598820

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3154881A Pending CA3154881A1 (en) 2019-11-04 2020-11-04 Her2/4-1bb bispecific fusion proteins for the treatment of cancer

Country Status (8)

Country Link
US (1) US20240166763A1 (https=)
EP (1) EP4054718A1 (https=)
JP (1) JP2023502876A (https=)
KR (1) KR20220097952A (https=)
CN (1) CN116348478A (https=)
AU (1) AU2020379176A1 (https=)
CA (1) CA3154881A1 (https=)
WO (1) WO2021089588A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541482A (ja) 2020-09-18 2023-10-02 ピエリス ファーマシューティカルズ ゲーエムベーハー バイオマーカー法および使用法
EP4644417A4 (en) * 2022-12-30 2026-02-11 Abclon Inc AFFICORPS SPECIFICALLY BINDING TO CD137 AND ITS USE
CN116103244A (zh) * 2023-04-12 2023-05-12 河北科技大学 一种单信号激活型til细胞的制备方法及应用
KR20250148463A (ko) * 2024-04-03 2025-10-14 주식회사유한양행 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2003029471A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
JP6783797B2 (ja) 2015-05-04 2020-11-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
CN114573680A (zh) 2015-05-04 2022-06-03 皮里斯制药有限公司 Cd137特异性的蛋白

Also Published As

Publication number Publication date
US20240166763A1 (en) 2024-05-23
KR20220097952A (ko) 2022-07-08
CN116348478A (zh) 2023-06-27
AU2020379176A1 (en) 2022-06-09
JP2023502876A (ja) 2023-01-26
EP4054718A1 (en) 2022-09-14
WO2021089588A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
JP6783797B2 (ja) 抗がん融合ポリペプチド
AU2019202283B2 (en) Trispecific binding proteins and methods of use
US20230366884A1 (en) Biomarker methods and uses
US20240166763A1 (en) Her2/4-1bb bispecific fusion proteins for the treatment of cancer
US20240166764A1 (en) Her2/4-1bb bispecific fusion proteins for the treatment of cancer
CN114423284A (zh) T细胞调节多肽及其使用方法
US20210246219A1 (en) Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
JP7544598B2 (ja) 免疫チェックポイント経路阻害剤と併用したインターロイキン－１０の組成物および使用方法
JP2008500811A (ja) 修飾ブーゲニンタンパク質、サイトトキシン、ならびにそれらの方法および使用
JP2022553129A (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
WO2022200478A1 (en) Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
EP2985292A1 (en) Epidermal growth factor receptor antibody
JP2025532652A (ja) Ｃｄ１３７およびｃｄ２２８に特異的な新規融合タンパク質
KR100958943B1 (ko) 쥐알파12/쥐알파13 단백질 기능의 하향 조절제를 포함하는전환성장인자베타 1 (티쥐에프 베타 1) 관련 질병의 예방또는 치료용 약학 조성물
CN114616247A (zh) Ox40/pd-l1双特异性抗体
WO2025175123A1 (en) Methods of treating cancer using fusion proteins specific for cd137 and cd228
JP2026502831A (ja) Ｐｄ－ｌ１を標的としｇａｓ６を中和する融合タンパク質及びその使用
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220803